<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:chebi fb="0" ids="25354">Mineralocorticoid</z:chebi> receptor (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>) <z:chebi fb="68" ids="48706">antagonists</z:chebi> have protective effects in the brain during experimental <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo>, and we have previously demonstrated a key role for myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> during <z:hpo ids='HP_0001297'>stroke</z:hpo> pathogenesis </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we explore both model- and sex-specific actions of myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> during <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS AND RESULTS: The <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> <z:chebi fb="68" ids="48706">antagonist</z:chebi> <z:chebi fb="0" ids="31547">eplerenone</z:chebi> significantly reduced the <z:mpath ids='MPATH_124'>infarct</z:mpath> size in male (control, 99.5 mm(3); <z:chebi fb="0" ids="31547">eplerenone</z:chebi>, 74.2 mm(3); n=8 to 12 per group) but not female (control, 84.0 mm(3); <z:chebi fb="0" ids="31547">eplerenone</z:chebi>, 83.7 mm(3); n=6 to 7 per group) mice after transient (90-minute) middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="3" pm="."><plain>In contrast to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> antagonism, genetic ablation of myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> in female mice significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> size (myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> knockout, 9.4 mm(3) [5.4 to 36.6]; control, 66.0 mm(3) [50.0 to 81.4]; n=6 per group) after transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>This was accompanied by reductions in inflammatory gene expression and improvement in neurological function </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast to <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>-reperfusion, myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e>-knockout mice were not protected from permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="6" pm="."><plain>The <z:mpath ids='MPATH_124'>infarct</z:mpath> size and <z:mp ids='MP_0001845'>inflammatory response</z:mp> after permanent occlusion showed no evidence of protection by myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> knockout in photothrombotic and intraluminal filament models of permanent occlusion </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: These studies demonstrate that <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> antagonism is protective in male but not female mice during transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, whereas genetic ablation of myeloid <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MR</z:e> is protective in both male and female mice </plain></SENT>
<SENT sid="8" pm="."><plain>They also highlight important mechanistic differences in the role of myeloid cells in different models of <z:hpo ids='HP_0001297'>stroke</z:hpo> and confirm that specific myeloid phenotypes play key roles in <z:hpo ids='HP_0001297'>stroke</z:hpo> protection </plain></SENT>
</text></document>